Hints and tips:
Related Special Reports
Related Topics
...Barclays analyst Emily Field believes Anderson must “at a minimum” follow the example of Sanofi, which in October named an earliest date by which it intended to carve out its own consumer healthcare business...
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager....
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
...They produce prescription drugs against cancer, heart disease and other illness, over-the-counter healthcare products like Bepanthen cream as well as seeds and herbicides for farmers....
...Bayer’s criticism of European and British health policies coincided with a visit by Nus Ghani, the UK’s minister of state at the department of business, energy and industrial strategy, to JPMorgan Healthcare...
...Management has not shown a strong propensity to disrupt the status quo,” he added, noting that the company trades at steep discounts to rivals in each of its three business divisions: pharmaceuticals, consumer healthcare...
...Consider Rajah & Tann’s work for Bayer on the use of drones. The pharmaceutical and chemicals conglomerate uses drones to help farmers in south-east Asia access more accurate and useful weather data....
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...Meanwhile, Germany’s Bayer in January said it was cutting jobs in Britain because of the UK medicines levy....
...Bayer’s pharmaceutical arm is reducing its UK footprint and cutting jobs. Our own domestic titans, GSK and AZ, have chosen to build new factories in countries more friendly to business....
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...Syzygy Healthcare Solutions and other manufacturers of generic versions of Plan B, such as Take Action and AfterPill, will also benefit....
...US media and healthcare companies are among those to have slashed the value of business units in the past few months, and accountants at valuation service Stout are warning that more cuts could be imminent...
...The UK spends a smaller proportion of its gross domestic product on healthcare than most other OECD countries, he said, and a smaller part of its healthcare budget on drugs....
...The architect of the healthcare strategy, Frans van Houten, left Philips last month. Litigation from afflicted US patients looms....
...Some in the medical sector are sceptical that AI drug discovery will fulfil its hype, pointing to the need to navigate strict regulations and integrate into dated healthcare systems....
...The team offers a global perspective on telehealth, which is the use of technology to access healthcare and related digital health products....
...“Supply chains have broken down because of the fighting and there is an urgent need to get healthcare supplies to people under siege,” said Pasko, who is liaising with healthcare vendors, logistics companies...
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
...Bayer is set to buy a Californian biopharmaceuticals start-up for up to $2bn as the German drugs and agrochemicals group pushes into novel therapeutic and research approaches in healthcare....
...Temasek last month is reported to have pushed for Bayer chief executive Werner Baumann to leave the German healthcare group....
...German drug and agrochemical conglomerate Bayer has also threatened to suspend crop sales to Russia next year unless it stops attacking Ukraine....
...His replacement Liam Condon is best known as the Bayer divisional boss who handled the German group’s ill-fated purchase of Monsanto....
...He will be succeeded by Liam Condon, who is departing his role as president of Bayer’s crop science division. Neil Evans is rejoining Clifford Chance as a private equity partner, based in London....
International Edition